INSIGHTS

Insights that cut through complexity

Six months after authorization, what do we know about Paxlovid?

Six months after authorization, what do we know about Paxlovid?

See this article by RemedyOne EVP of clinical services Robert Louie as it originally appeared in Pharmaphorum.  It has now…
How the pharmaceutical industry can turn the tide on mental health

How the pharmaceutical industry can turn the tide on mental health

May is Mental Health Awareness Month. RemedyOne president Ralph Pisano wrote this article for Fierce Healthcare about how the pharmaceutical…
New Developments in Macular Degeneration/Diabetic Eye Disease

New Developments in Macular Degeneration/Diabetic Eye Disease

Visual impairment can be a major health issue for older adults, ranging from a minor inconvenience to vision loss significantly…
Drug Innovation Continues Despite a World-Wide Pandemic

Drug Innovation Continues Despite a World-Wide Pandemic

While much of the world was on pause during the COVID-19 pandemic, there are definite signs that even a pandemic…
Three pharmacy trends that will define 2022

Three pharmacy trends that will define 2022

See article as it originally appeared in MedCity News.  The pharmaceutical industry made more headlines in 2021 than in any…
2022 Q1 RemedyOne Quarterly Pipeline Report

2022 Q1 RemedyOne Quarterly Pipeline Report

Download our 2022 Q1  Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in…
Like what you’re seeing? Get more Insights sent to you.
  • This field is for validation purposes and should be left unchanged.